Characterization of Bacillus probiotics available for human use.
Bacillus species (Bacillus cereus, Bacillus clausii, Bacillus pumilus) carried in five commercial probiotic products consisting of bacterial spores were characterized for potential attributes (colonization, immunostimulation, and antimicrobial activity) that could account for their claimed probiotic properties. Three B. cereus strains were shown to persist in the mouse gastrointestinal tract for up to 18 days postadministration, demonstrating that these organisms have some ability to colonize. Spores of one B. cereus strain were extremely sensitive to simulated gastric conditions and simulated intestinal fluids. Spores of all strains were immunogenic when they were given orally to mice, but the B. pumilus strain was found to generate particularly high anti-spore immunoglobulin G titers. Spores of B. pumilus and of a laboratory strain of B. subtilis were found to induce the proinflammatory cytokine interleukin-6 in a cultured macrophage cell line, and in vivo, spores of B. pumilus and B. subtilis induced the proinflammatory cytokine tumor necrosis factor alpha and the Th1 cytokine gamma interferon. The B. pumilus strain and one B. cereus strain (B. cereus var. vietnami) were found to produce a bacteriocin-like activity against other Bacillus species. The results that provided evidence of colonization, immunostimulation, and antimicrobial activity support the hypothesis that the organisms have a potential probiotic effect. However, the three B. cereus strains were also found to produce the Hbl and Nhe enterotoxins, which makes them unsafe for human use.
Duc
Le H
le H
School of Biological Sciences, Royal Holloway, University of London, Egham, Surrey TW20 OEX, United Kingdom.
Hong
Huynh A
HA
Barbosa
Teresa M
TM
Henriques
Adriano O
AO
Cutting
Simon M
SM
D000818:Animals; D001407:Bacillus / Q000472:pathogenicity / Q000502:physiology; D001409:Bacillus cereus / Q000472:pathogenicity / Q000502:physiology; D004768:Enterotoxins / Q000096:biosynthesis; D005260:Female; D041981:Gastrointestinal Tract / Q000276:immunology / Q000382:microbiology; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D007375:Interleukin-1 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D051379:Mice; D008810:Mice, Inbred C57BL; D019936:Probiotics / Q000009:adverse effects; D012449:Safety; D013171:Spores, Bacterial; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis; D014774:Virulence
D004768:Enterotoxins; D007375:Interleukin-1; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma